N-[(2-tert-butyl-benzenesulfonyl)-phenyl]-2,3,4-trihydroxy-5-(2-isopropyl-benzyl)-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2-tert-butyl-benzenesulfonyl)-phenyl]-2,3,4-trihydroxy-5-(2-isopropyl-benzyl)-benzamide
• 英文别名: N-[(2-t-butyl-benzenesulfonyl)-phenyl]-2,3,4-trihydroxy-5-(2-isopropyl-benzyl)-benzamide；N-[2-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide
• 化学式: C₃₃H₃₅NO₆S
• 分子量: 573.71
• InChiKey: UTESRKXSJMLCIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161A2

  公开（公告）日：2015-05-20
• DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161B1

  公开（公告）日：2020-12-16
• METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR
  申请人：Del Mar Pharmaceuticals (BC) Ltd.

  公开号：US20210251944A1

  公开（公告）日：2021-08-19

  Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI-1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI-1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI-1 gene or AHI-1 protein, and the compositions can further include such an agent.
• [EN] METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF<br/>[FR] MÉTHODES DE TRAITEMENT DE MALIGNITÉS RÉSISTANTES À UN INHIBITEUR DE TYROSINE KINASE CHEZ DES PATIENTS AYANT DES POLYMORPHISMES GÉNÉTIQUES OU DES DÉRÉGULATIONS OU DES MUTATIONS D'AHI1 À L'AIDE DE DIANHYDROGALACTITOL, DIACÉTYLDIANHYDROGALACTITOL, DIBROMODULCITOL OU DES ANALOGUES OU DÉRIVÉS CORRESPONDANTS
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2014004376A2

  公开（公告）日：2014-01-03

  Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI1 gene or AHI1 protein, and the compositions can further include such an agent.
• [EN] METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING MYELOMA<br/>[FR] PROCÉDÉS ET COMPOSITIONS PERMETTANT DE PRÉDIRE ET TRAITER LE MYÉLOME
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017202890A1

  公开（公告）日：2017-11-30

  The inventors have used the Εμ-bcl-b transgenic mouse model to study the effect of the Blc-B protein on the evolution of monoclonal gammopathy of undetermined significance (MGUS) to myeloma. They have performed the Bcl-B-positive plasma cell quantification by flow cytometry analysis of bone marrow cells from an MGUS and an multiple myeloma (MM) patient. They have showed that a subject having a high concentration of Bcl-B than a predetermined value is at risk of having myeloma. Accordingly, the invention relates to a method for predicting the risk of having myeloma in a subject suffering from MGUS comprising the steps of: i) measuring the concentration of Bcl-B in a biological sample obtained from said subject, ii) comparing the concentration obtained at step (i) to a predetermined value, and iii) concluding that the subject is at risk of having myeloma when the concentration of Bcl-B is higher than the predetermined value.